Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Ayala Pharmaceuticals Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
ADXS
Over the counter
8731
https://ayalapharma.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Ayala Pharmaceuticals Inc
Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome
- Mar 26th, 2024 12:00 pm
Ayala Pharmaceuticals Announces Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors
- Feb 20th, 2024 1:00 pm
Immunome to Acquire AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals
- Feb 6th, 2024 1:00 pm
Ayala Pharmaceuticals Announces AL102 Receives Orphan Drug Designation for Desmoid Tumors
- Nov 6th, 2023 1:00 pm
Ayala Pharmaceuticals Presents Updated AL102 Results from Phase 2 Clinical Trial in Desmoid Tumors at ESMO Congress 2023
- Oct 23rd, 2023 11:00 am
Ayala Pharmaceuticals Announces Closing of Merger with Biosight
- Oct 19th, 2023 12:00 pm
Ayala Pharmaceuticals Announces Second Quarter 2023 Financial Results and Provides Corporate Update
- Aug 10th, 2023 8:30 pm
Ayala Pharmaceuticals Announces Abstracts on AL102 and AL101 Accepted for Presentation at ESMO Congress 2023
- Aug 1st, 2023 12:00 pm
Ayala Pharmaceuticals and Biosight Enter into Definitive Merger Agreement
- Jul 27th, 2023 12:10 pm
Ayala Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA Regarding AL102 for the Treatment of Desmoid Tumors
- Jul 5th, 2023 12:00 pm
Updated RINGSIDE Phase 2 Results Featured in Poster Discussion Session at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
- Jun 5th, 2023 12:00 pm
Ayala Pharmaceuticals Announces Updated RINGSIDE Phase 2 Results at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
- May 25th, 2023 9:05 pm
Ayala Pharmaceuticals Announces First Quarter 2023 Financial Results and Provides Corporate Update
- May 23rd, 2023 5:20 pm
Ayala Pharmaceuticals Announces RINGSIDE Results to be Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
- Apr 27th, 2023 12:00 pm
Scroll